BACKGROUND AND PURPOSE:Activated Protein C (APC) stimulates multiple cytoprotective pathways via the protease activated receptor-1 (PAR-1) and promotes anticoagulation. 3K3A-APC was designed for preserved activity at PAR-1 with reduced anticoagulation. This Phase 1 trial characterized pharmacokinetics and anticoagulation effects of 3K3A-APC. METHODS:Subjects (n=64) were randomly assigned to receive 3K3A-APC (n=4) at 6, 30, 90, 180, 360, 540 or 720 µg/kg or placebo (n=6) and were observed for 24 hr. After safety review additional subjects received drug every 12 hr for 5 doses (n=6 per group) at 90, 180, 360, or 540 µg/kg or placebo (n=8) and were observed for 24 hr. RESULTS: All subjects returned for safety assessments at 72 hours and 15 days. We found few adverse events in all groups. Systolic blood pressure increased in both active and placebo groups. Moderately severe headache, nausea and vomiting were reported in one of two subjects treated with 720 µg/kg so 540 µg/kg was considered the highest tolerated dose. Mean plasma concentrations increased in proportion to dose. Clearance ranged from 11,693 ± 807 to 18,701 ± 4,797 mL/hr, volume of distribution ranged from 4,873±828 to 6,971 ± 1,169 mL, and elimination half-life ranged from 0.211 ± 0.097 to 0.294 ± 0.054 hours. Elevations in aPTT were minimal. CONCLUSIONS:3K3A-APC was well tolerated at multiple doses as high as 540 µg/kg. These results should be confirmed in stroke patients with relevant co-morbidities. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01660230.
RCT Entities:
BACKGROUND AND PURPOSE:Activated Protein C (APC) stimulates multiple cytoprotective pathways via the protease activated receptor-1 (PAR-1) and promotes anticoagulation. 3K3A-APC was designed for preserved activity at PAR-1 with reduced anticoagulation. This Phase 1 trial characterized pharmacokinetics and anticoagulation effects of 3K3A-APC. METHODS: Subjects (n=64) were randomly assigned to receive 3K3A-APC (n=4) at 6, 30, 90, 180, 360, 540 or 720 µg/kg or placebo (n=6) and were observed for 24 hr. After safety review additional subjects received drug every 12 hr for 5 doses (n=6 per group) at 90, 180, 360, or 540 µg/kg or placebo (n=8) and were observed for 24 hr. RESULTS: All subjects returned for safety assessments at 72 hours and 15 days. We found few adverse events in all groups. Systolic blood pressure increased in both active and placebo groups. Moderately severe headache, nausea and vomiting were reported in one of two subjects treated with 720 µg/kg so 540 µg/kg was considered the highest tolerated dose. Mean plasma concentrations increased in proportion to dose. Clearance ranged from 11,693 ± 807 to 18,701 ± 4,797 mL/hr, volume of distribution ranged from 4,873±828 to 6,971 ± 1,169 mL, and elimination half-life ranged from 0.211 ± 0.097 to 0.294 ± 0.054 hours. Elevations in aPTT were minimal. CONCLUSIONS: 3K3A-APC was well tolerated at multiple doses as high as 540 µg/kg. These results should be confirmed in strokepatients with relevant co-morbidities. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01660230.
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: H P Adams; B H Bendixen; E Leira; K C Chang; P H Davis; R F Woolson; W R Clarke; M D Hansen Journal: Neurology Date: 1999-07-13 Impact factor: 9.910
Authors: Tong Cheng; Dong Liu; John H Griffin; José A Fernández; Francis Castellino; Elliot D Rosen; Kenji Fukudome; Berislav V Zlokovic Journal: Nat Med Date: 2003-02-03 Impact factor: 53.440
Authors: Huang Guo; Dong Liu; Harris Gelbard; Tong Cheng; Rae Insalaco; José A Fernández; John H Griffin; Berislav V Zlokovic Journal: Neuron Date: 2004-02-19 Impact factor: 17.173
Authors: Laura D Healy; Cristina Puy; José A Fernández; Annachiara Mitrugno; Ravi S Keshari; Nyiawung A Taku; Tiffany T Chu; Xiao Xu; András Gruber; Florea Lupu; John H Griffin; Owen J T McCarty Journal: J Biol Chem Date: 2017-04-13 Impact factor: 5.157
Authors: Padmesh S Rajput; Jessica A Lamb; Jose Á Fernández; Jilin Bai; Benedict R Pereira; I-Farn Lei; Jennifer Leung; John H Griffin; Patrick D Lyden Journal: Brain Res Date: 2019-03-14 Impact factor: 3.252
Authors: P S Rajput; P D Lyden; B Chen; J A Lamb; B Pereira; A Lamb; L Zhao; I-F Lei; J Bai Journal: Neuroscience Date: 2014-09-28 Impact factor: 3.590
Authors: Laurent Burnier; Amin Boroujerdi; Jose A Fernández; Jennifer V Welser-Alves; John H Griffin; Richard Milner Journal: Exp Neurol Date: 2016-07-10 Impact factor: 5.330
Authors: John H Griffin; Laurent O Mosnier; José A Fernández; Berislav V Zlokovic Journal: Arterioscler Thromb Vasc Biol Date: 2016-10-06 Impact factor: 8.311
Authors: Patrick Lyden; Kent E Pryor; Christopher S Coffey; Merit Cudkowicz; Robin Conwit; Ashutosh Jadhav; Robert N Sawyer; Jan Claassen; Opeolu Adeoye; Shlee Song; Peter Hannon; Natalia S Rost; Archana Hinduja; Michel Torbey; Jin-Moo Lee; Curtis Benesch; Michael Rippee; Marilyn Rymer; Michael T Froehler; E Clarke Haley; Mark Johnson; Jon Yankey; Kim Magee; Julie Qidwai; Howard Levy; E Mark Haacke; Miller Fawaz; Thomas P Davis; Arthur W Toga; John H Griffin; Berislav V Zlokovic Journal: Ann Neurol Date: 2019-01-07 Impact factor: 10.422